What are you searching for?

Sign in
Breaking News, Promotions & Moves

Vasomune Appoints New CEO

Douglas A. Hamilton was also appointed President of the company, and will serve on Vasomune’s Board of Directors

Vasomune Therapeutics has appointed Douglas A. Hamilton as president and chief executive officer of the company. Mr. Hamilton will also be appointed to Vasomune’s Board of Directors. 
 
“I am delighted to be joining Vasomune and its team of founders, dedicated scientists, consultants and high-profile institutional investors,” said Mr. Hamilton.  “By selectively targeting the host response, Vasomune’s therapeutic approach focuses on a single, non-redundant pathway that inhibits multiple factors responsible for driving run-away inflammatory processes.” 
 
Most recently Mr. Hamilton served as president and chief executive officer of MetaStat Inc., a precision medicine company discovering and developing novel anti-metastatic drugs for the treatment of patients with aggressive cancer.   


Mr. Hamilton will succeed Parimal Nathwani, who will remain on the Board of Directors.
 
“We are thrilled to welcome Doug to the leadership role at Vasomune during this exciting time in the company’s history – he has the management expertise required to transition the company from a preclinical to clinical stage,” says Rafi Hofstein, president and chief executive officer of MaRS Innovation, the founding investor of Vasomune. “Attracting an accomplished leader like Doug to Toronto is part of our efforts to entice expats to return to Canada where there is a need for highly trained executives to become involved in steering start-up companies to success.”
 
“On behalf of the board and shareholders, I would like to thank Parimal Nathwani for his leadership in creating and guiding Vasomune Therapeutics to its current stage of development, including raising seed financing and orchestrating the co-development deal with Japan-based AnGes Inc, “ said Michael Yonge, director and executive vice president and chief administration officer of Sunnybrook Health Sciences Centre.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters